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Acute porphyrias are inherited disorders caused by partial deficiency of specific heme
biosynthesis enzymes. Clinically, porphyrias are manifested by a neuropsychiatric
syndrome that includes peripheral neuropathy. Although much is known about the
porphyrias’ enzyme defects and their biochemical consequences, the cause of the
neurological manifestations remains unresolved. We have studied porphyric neuropathy in
mice with a partial deficiency of porphobilinogen deaminase (PBGD). PBGD-deficient mice
(PBGD–/–) imitate acute porphyria through massive induction of hepatic d-aminolevulinic
acid synthase by drugs such as phenobarbital. Here we show that PBGD–/– mice develop
impairment of motor coordination and muscle weakness. Histologically femoral nerves of
PBGD–/– mice exhibit a marked decrease in large-caliber (>8 µm) axons and ultrastructural
changes consistent with primary motor axon degeneration, secondary Schwann cell
reactions, and axonal regeneration. These findings resemble those found in studies of
affected nerves of patients with acute porphyria and thus provide strong evidence that
PBGD deficiency causes degeneration of motor axons without signs of primary
demyelination, thereby resolving a long-standing controversy. Interestingly, the neuropathy
in PBGD–/– mice developed chronically and progressively and in the presence of normal or
only slightly (twofold) increased plasma and urinary levels of the putative neurotoxic heme
precursor d-aminolevulinic acid. These data suggest that heme deficiency and consequent
dysfunction of hemeproteins can cause porphyric neuropathy.
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Introduction
Four types of acute hepatic porphyria — acute intermit-
tent porphyria (AIP), hereditary coproporphyria (HCP),
variegate porphyria (VP), and d -aminolevulinic acid
dehydratase (ALAD) deficiency porphyria — are clinical-
ly associated with an identical neurological syndrome.
Manifestations of acute, life-threatening attacks include
autonomic neuropathy with abdominal pain, vomiting,
constipation, hypertension, tachycardia, and bladder
dysfunction. Other manifestations are peripheral neu-
ropathy causing motor weakness and paralysis and men-
tal symptoms that occur without detectable morpho-
logical anomalies in the brain (1–4).
Acute porphyrias result from dominantly (AIP, HCP,
VP) or recessively (ALAD deficiency) inherited partial
deficiency of specific enzymes in heme biosynthesis.
Attacks of clinical symptoms frequently are precipitated
by drugs, alcohol, fasting, or hormonal changes associ-
ated with the menstrual cycle (3).
The pathogenesis of porphyric neuropathy and its pre-
cipitation by drugs or other factors have remained enig-
matic partly because of the lack of an experimental model.
For these reasons, we have developed a mouse model of AIP
by partially disrupting porphobilinogen deaminase
(PBGD) by gene targeting (5). PBGD-deficient mice
(PBGD–/–) recapitulate the drug-precipitated biochemical
abnormalities of acute porphyria in humans and develop
some neuropathological features resembling those of
patients with the inherited disease. This experimental
model should allow testing of various hypotheses proposed
as possible mechanisms of porphyric neuropathy, includ-
ing neurotoxicity of d -aminolevulinic acid (ALA) and heme
deficiency in nervous tissues (4, 6).
A number of clinical observations associate ALA with
acute porphyria. Thus, acute attacks, including motor neu-
ropathy, invariably are accompanied by increased activity of
hepatic ALA synthase and increased plasma levels and uri-
nary excretion of ALA (1, 3). Treatments considered effec-
tive, such as high carbohydrate intake or heme infusion,
lower ALA excretion (7). Moreover, in tyrosinemia type I
and acute lead poisoning, urinary ALA excretion is
increased; in both conditions, symptoms resembling those
of acute porphyria, such as abdominal pain and peripheral
neuropathy, occur. ALA exerts a number of effects in bio-
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logical systems in vitro, including interactions with g -
aminobutyric acid (GABA) receptors (8) and free radical for-
mation (9). However, many of these effects occur at rela-
tively high concentrations that are unlikely to exist in
tissues during acute attacks. Arguments against the ALA
hypothesis are the high excretion of ALA in many asymp-
tomatic patients and the lack of clinical signs of neurolog-
ical dysfunction after ALA administration in healthy vol-
unteers or patients with acute porphyria (reviewed in ref. 4).
Extensive studies in rodents involving oral and parenteral
administration of ALA for up to several weeks also failed to
produce significant toxic, behavioral, or pharmacological
effects (10). However, ALA given in the setting of normally
regulated heme synthesis (i.e., without partial deficiency of
a specific enzyme) may not reflect the pathophysiological
situation of porphyria. Therefore, the question whether
ALA can produce some, or even all, of the manifestations of
acute porphyria has remained a controversial issue. Con-
nected with this uncertainty is the unresolved question
regarding actual ALA concentrations in the central and
peripheral nervous systems or to what extent ALA overpro-
duced in the liver may cross the blood-brain barrier (11).
In the present study, we have used behavioral tests,
light and electron microscopy, and electrophysiological
techniques to examine the development of peripheral
neuropathy of PBGD–/– mice of different ages. Our data
document a chronic and progressive axonal motor neu-
ropathy that morphologically resembles the neuropa-
thy of porphyria patients. Further experiments were car-
ried out to determine the concentration of ALA in brain
and peripheral tissue in PBGD–/– mice. Our data reveal
that the motor neuropathy in PBGD–/– mice develops at
normal or only slightly increased ALA concentration,
making neurotoxicity of ALA an unlikely mechanism of
porphyric neuropathy.
Methods
Animals and treatments. PBGD-deficient mice used in this study
have previously been described (5). PBGD was partially inacti-
vated by gene targeting so that one allele of PBGD had a loss of
function disruption and the other allele a partial disruption.
Compound heterozygous mice (designated PBGD-deficient, or
PBGD–/–) have 25–30% of normal PBGD activity. Age- and gen-
der-matched normal C57BL/6 wild-type (+/+) mice were used
as controls. Mice were maintained in a 12-hour light/12-hour
dark cycle and had free access to standard rodent laboratory
chow and drinking water. The animals were studied at various
ages: old (15.5–20.5 months), middle (six months), and young
(two to three months). To biochemically imitate a human por-
phyric attack, mice were treated with increasing doses (100,
110, 120, and 125 mg/kg) of phenobarbital intraperitoneally
for four consecutive days (5).
Behavioral studies. Standard behavioral tests were selected to
evaluate motor function in PBGD–/– mice (12). The rotorod
test measures motor coordination and proprioceptive sensitiv-
ity. It determines the time (in seconds) that mice can stay on a
rotating dowel turning at 12 rpm. In addition, the motor coor-
dination was studied on an inclined plane, where the angle at
which mice can no longer remain on the plane is determined.
The walk-on-a-rod test evaluates the time required (in seconds)
to cross a 40-cm-long rod 10 mm in diameter. The hot plate test
examines the escape reaction: the time (in seconds) that elaps-
es until the mouse jumps out of a glass cylinder (17 cm high
and 9 cm in diameter) with the base plate at 48°C. Muscular
endurance was quantified by determination of the time (in sec-
onds) an animal keeps hold of a weight (32 g) with two of its
legs when lifted by the tail. Maximal strength (in newtons) was
measured with the mouse pulling a piece of wire connected to
an isometric transducer. Pain threshold was determined by the
tail-flick test and the occurrence of the paw-lick response dur-
ing hot plate tests. In the tail-flick test, an intense light beam is
focused on the tail, and the time (in seconds) that passes until
the animal flicks its tail is determined.
Light and electron microscopy. The femoral nerve (comprising
branches of the quadriceps muscle and the cutaneous saphe-
nous nerve) was processed for light and electron microscopy as
recently described (13, 14). Snap-frozen and unfixed cryosec-
tions (6 m m) were subjected to indirect immunoperoxidase
staining with antibodies against the myelin-specific protein zero
(P0) (P0, mAb anti-P0, clone D41E4 provided by S.L. Miller, Chil-
dren’s Hospital, Philadelphia, Pennsylvania, USA; ref. 15)  and
against the glial fibrillary acidic protein (GFAP) (GFAP, poly-
clonal rabbit anti-GFAP purchased from DAKO A/S, Golstrup,
Denmark) and included negative controls for the secondary per-
oxidase–labeled antibodies (goat anti-mouse IgG [Fc] P0-Ab and
goat anti-rabbit IgG [whole molecule] P0-Ab; Sigma Chemical
Co., St. Louis, Missouri, USA). Counts of myelinated axons were
performed on micrographs of toluidine blue–stained semi-thin
plastic sections (1 m m) of the quadriceps muscle branch of the
femoral nerve at a final magnification of · 800.
Electrophysiology. Investigation of nerve conduction charac-
teristics of facial and sciatic nerves in 21 (15.5–20.5 months old)
PBGD–/– mice and 16 gender- and age-matched
control mice were performed with methods
described previously (16). Electromyography in
five PBGD–/– and four control mice was done
with a Tönnies digital electromyograph (Tön-
nies, Würzburg, Germany) with a concentric
needle electrode. Motor unit action potentials
(MUAPs) were elicited by gently pressing on the
opposite limb to induce a withdrawal response.
Microdialysis and ALA measurements. Microdial-
ysis (17) allows continuous monitoring of sub-
stances from the extracellular space in tissues
and organs in vivo with minimal perturbation
of the physiological system, i.e., without con-
tamination by blood. The microdialysis probe
(CMA12; shaft length 6 mm, diameter 0.5 mm,
membrane length 2 mm, pore size 20 kDa;
Carnegie Medicine AB, Stockholm, Sweden)
was placed by a stereotaxic device into the stria-
tum to estimate central nervous system concen-
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Table 1
Motor coordination and muscular performance in female mice
Age (months)
Test Mouse 3 6 16
Rotorod PBGD–/– 151.2 – 29.3 35.2 – 21.5A 1.2 – 0.4A
(s) control 180B 161.4 – 11.8 163.6 – 16.4
Walk on rod PBGD–/– 3.0 – 0.5 4.2 – 0.8 51.8 – 8.3A
(s) control 2.2 – 0.2 1.8 – 0.4 4.2 – 0.4
Inclined plane PBGD–/– 80.2 – 2.2 78.6 – 2.6C 67.4 – 4.5D
(°) control 88.4 – 5.0 86.2 – 1.0 78.8 – 2.0
Escape reaction PBGD–/– 9.0 – 2.8 45A,E 45A,E
(s) control 10.0 – 1.1 3.0 – 0.7 6.8 – 1.4
Muscular endurance PBGD–/– 51.8 – 4.0 40.2 – 9.1 32.8 – 8.0D
(s) control 56.8 – 2.0 46.6 – 8.5 57.2 – 2.9
Maximal strength PBGD–/– 0.025 – 0.002 0.018 – 0.002C 0.012 – 0.002A
(N) control 0.028 – 0.002 0.023 – 0.002 0.023 – 0.004
Data represent mean – SEM (n = 5). PBGD–/– mice are compared with age-matched wild-type control mice.
AP < 0.001. B180 s, time limit of the test. CP <0.01. DP <0.05. E45 s, time limit of the test.
trations. In other experiments, the probe was placed close to the
tibial nerve of the hindleg to derive peripheral tissue concen-
trations. Samples of extracellular fluid (ECF) were collected,
and ALA levels in the ECF of striatum and peripheral tissue, as
well as in blood and urine, were analyzed with an HPLC
method (18).
Statistical analysis. Differences in the number of myelinated axons
of the femoral nerve were analyzed by using Student’s t test. The
double-sided U test (InStat; GraphPad Software for Science Inc.,
San Diego, California, USA) was applied to electrophysiological
and electromyographical data. Behavioral tests were analyzed by
ANOVA combined with the Scheffé post hoc test.
Results
Behavioral studies of motor function. Motor dysfunction was
evident in all behavioral tests (Table 1) in old PBGD–/–
mice (age 16 months) compared with age-matched con-
trols. In particular, in the rotorod test, old PBGD–/– mice
were unable to stay on the turning rod and unable to
escape from a cylinder placed on a hot plate (escape reac-
tion). Motor disturbance was already demonstrable at six
months for the rotorod, inclined plane, and maximal
strength tests, as well as for the escape reaction, but for
three-month-old mice the differences were not statisti-
cally significant.
Sensory deficits were not obvious in PBGD–/– mice of any
age. Thus, pain threshold, measured with tail-flick or paw-
lick response during a hot plate test, was not different in
PBGD–/– and control mice (data not shown).
Light microscopy and immunohistochemistry of peripheral
nerves. The most striking finding in quadriceps nerves
from 17-month-old PBGD–/– mice was a reduction in the
number of large axons (diameter >8 m m). These large
axons decreased by 90% (from 139 to 14; Figure 1, e–g).
The overall diameter of all quadriceps nerves investigat-
ed also was strongly reduced in old PBGD–/– mice. At six
months of age, the reduction of large-caliber axons was
~ 60% (from 141 to 53; Figure 1, c, d, and g). At this age,
extended regions of the endoneurium were occupied by
cellular profiles that were devoid of myelin (Figure 1d).
Contorted myelin and myelin ovoids were also observed,
indicating degenerative events. In quadriceps nerves from
two-month-old PBGD–/– mice, neither loss of large-cal-
iber axons nor myelin profiles suggesting degeneration
were observed (Figure 1, a, b, and g). Immunohistochem-
istry with antibodies against the myelin component P0
confirmed the light microscopy findings in aged mice
(Figure 2, a and c). A prominent feature was the increased
expression of GFAP, an established marker of nonmyeli-
nating and denervated Schwann cells (Figure 2).
Electron microscopy. Striking ultrastructural abnormalities
were found in quadriceps nerves in PBGD–/– mice six and
17 months old. In addition to the reduced numbers of
large-caliber fibers, the presence of basal lamina–covered
Schwann cell profiles devoid of axons and myelin was the
most frequent pathological alteration (Figure 3, a and b).
These structures represent most probably denervated
Schwann cells (bands of Büngner) and were often situated
close to axon-Schwann cell units with normally shaped or
thin myelin (Figure 3a). The bands of Büngner were occa-
sionally associated with axonal growth cones (Figure 3c) or
with nonmyelinated small-caliber axons (Figure 3d).
Another striking characteristic was the presence of
myelinated axons with features suggesting axonal degen-
eration, such as overall high electron density, disorgan-
ized neurofilaments and neurotubules, and clusters of
electron-dense material apposed to the axolemma (Fig-
ure 4, a and b). Axonal membranes were often discontin-
uous, and the periaxonal compartment often was poorly
defined (Figure 4b). Absence of axonal mitochondria
(Figure 4, a and b) was also frequently observed. Another
typical feature was the occurrence of myelin-containing
Schwann cells that were devoid of an axon and charac-
terized by a contorted myelin structure reminiscent of
Wallerian degeneration (Figure 4, c and d). Approxi-
mately 5–10% of myelinated axon-Schwann cell units
exhibited the described degenerative phenotype.
Nonmyelinating Schwann cells ensheathing bundles
of small-caliber axons were also abnormally organized in
the quadriceps nerve of six- and 17-month-old mice, as
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Figure 1
Light micrographs of semi-thin plastic sections of femoral quadriceps nerves of con-
trol (a, c, and e) and PBGD–/– (b, d, and f) mice at two months (a and b), six months
(c and d), and 17 months (e and f) of age. (g) Number of axons in quadriceps nerves.
Numbers represent mean values from three mice ± SD. Largest axons were thicker than
5 m m in two-month-old mice and thicker than 8 m m in six- and 17-month-old mice.
*Significantly different compared with control mice (P < 0.05). **Significantly differ-
ent compared with control mice (P < 0.01). (a and b) At two months of age, there are
no pathological alterations in femoral quadriceps nerves of PBGD–/– mice. (c and d)
At six months of age, quadriceps nerves from PBGD–/– mice are characterized by a sig-
nificant loss of axonal profiles of larger caliber. In addition, abnormal myelin profiles
(arrows) and extended regions not occupied by myelinated fibers are typical findings.
(e and f) At 17 months of age, the overall diameter of the femoral nerve and the num-
ber of axonal profiles of larger caliber is strongly reduced. Scale bar: 10 m m.
reflected by slender cell processes protruding into the
endoneurial space (Figure 4e). By contrast, both myeli-
nated and nonmyelinated fibers appeared normal in the
saphenous nerve, the major sensory cutaneous branch of
the femoral nerve (Figure 4f).
In summary, the morphological findings are consis-
tent with degeneration of large-caliber axons, secondary
Schwann cell reactions, and axonal regeneration.
Electrophysiological investigations. We found a statistical-
ly significant decrease of the sciatic nerve motor
response (M-response) amplitude in PBGD–/– mice (Fig-
ure 5a). All other sciatic nerve conduction studies were
normal in the PBGD–/– mice compared with control mice
(Table 2). The shape of the M-response was usually
biphasic or triphasic. Slight temporal dispersion
occurred in five PBGD–/– mice but in only one control
mouse (Figure 5a). Four out of the five PBGD–/– mice
with temporal dispersion had low M-response ampli-
tudes (<10 mV). However, very low M-response ampli-
tudes also occurred in six PBGD–/– mice and two control
mice with no temporal dispersion. Mixed-afferent nerve
conduction was normal in the sciatic nerve of PBGD–/–
mice (Table 2). Facial nerve motor conduction studies,
including the absolute refractory time, were normal in
PBGD–/– mice (data not shown).
Electromyography studies were performed with the
greater gluteal muscle, the quadriceps, and the gastrocne-
mius muscle in control and PBGD–/– mice. Our main find-
ing was a significant increase of MUAP amplitudes in all
investigated muscles of PBGD–/– mice (Table 2 and Figure
5c). The short duration of MUAPs and the rapid recruit-
ment of muscle units precluded a detailed analysis of sin-
gle MUAP duration. We detected polyphasic MUAPs in
three out of five PBGD–/– mice (all in the greater gluteal
muscle, three out of 93 MUAPs analyzed; Figure 5b), fib-
rillation in one PBGD–/– mouse (quadriceps muscle), and
fasciculations in the greater gluteal and quadriceps mus-
cles of one PBGD–/– mouse. These observations are likely
to underestimate the true degree of abnormality because
of the high background activity. No pathological sponta-
neous activity occurred in control mice. The recruitment
pattern consisted of normal-appearing recruitment of
MUAPs with an amplitude of 250–1,000 m V, with an inter-
ference pattern on maximal withdrawal in control mice.
In PBGD–/– mice, however, early recruitment of high-
amplitude MUAPs occurred on muscle contraction, and
no dense interference pattern was obtained (Figure 5c).
Also, the discharge frequency of motor units was slightly
higher in PBGD–/– mice (range 30–140 Hz) compared with
control mice (range 14–70 Hz).
These findings are characteristic of a chronic axonopa-
thy predominantly affecting motor fibers. There is no
electrophysiological evidence for primary demyelination
or sensory nerve involvement.
ALA concentrations. Only a slight increase (approximately
twofold) in the plasma concentration and urinary excre-
tion of ALA was observed in PBGD–/– mice (Table 3). In
ECF near the tibial nerve of hindlimbs, ALA concentra-
tions were determined to be ~ 15–25% of the plasma levels
in both PBGD–/– and control mice. In striatum of PBGD–/–
and control mice, ALA was undetectable without drug
administration. Drugs such as phenobarbital induce ALA
synthase in the liver and precipitate acute attacks of por-
phyria. We therefore treated mice with phenobarbital to
increase the concentration of plasma ALA to levels
observed in patients during acute attacks of porphyria
(2–13 · 10–6 M; Table 3) (11). As expected, phenobarbital
treatment caused a massive (~ 50-fold) increase of ALA in
plasma in PBGD–/– mice, whereas the increase in controls
was only twofold (Table 3). Under these conditions, the
brain (striatum) ECF concentration of ALA rose from
undetectable to ~ 6 · 10–8 M in PBGD–/– mice and from
undetectable to ~ 2 · 10–9 M in controls. The plasma-to-
brain ratio of 120:1 and 250:1 suggests a high blood-brain
barrier for ALA. Of special interest in this investigation is
the fact that PBGD–/– mice developed motor neuropathy
without any drug treatment.
Discussion
PBGD–/– mice develop progressive muscle weakness and
loss of motor coordination with increasing age, as evi-
denced in behavioral tests. The disturbance of motor
1130 The Journal of Clinical Investigation | April 1999 | Volume 103 | Number 8
Figure 2
Immunostaining of myelin with antibodies against P0 (red color) and
GFAP (red color). Cryosections of the femoral nerve of a control mouse
(a and b) and a mouse with PBGD deficiency (c and d), both at 16
months of age. Scale bar: 20 m m.
function is most likely caused by a continuous decrease
in the number of larger-caliber axons in motor nerves,
with a reduction of 60% and 90% at six and 17 months of
age, respectively (Figures 1 and 2). The predominant
affliction of the larger-caliber axons has also been noted
in the few nerve biopsies performed in patients with por-
phyric peripheral neuropathy (6, 19). Apparently, degen-
erated axons have the ability to regenerate. The observa-
tion that the loss of large-caliber axons is higher than the
decrease in the total number of axons can be explained
by the regrowth and remyelination of axons that acquire
and maintain a small-caliber phenotype (Figure 1g). The
increased GFAP staining in the peripheral
nerves of PBGD–/– mice (Figure 2, b and d) also
is consistent with increased Schwann cell activ-
ity associated with regeneration of axons. A
further argument in favor of axonal regrowth
is the decreased recruitment and polyphasia of
MUAPs in PBGD–/– mice. The increase of
MUAP amplitudes also is consistent with
enlargement of motor unit size due to reinner-
vation, as is the observation of axonal growth
cones and axonal sprouts (Figure 3, c and d).
Electromyographic findings in human por-
phyric neuropathy usually also reveal decreased
recruitment of MUAPs shortly after onset of
weakness (20, 21).
The conspicuous absence of pathological
changes in the sensory saphenous nerve again
matches the clinical experience in porphyria
patients, as the peripheral neuropathy is chiefly
a motor paralysis; sensory disturbances are min-
imal and late, if they appear at all (2, 4, 6, 22).
Our interpretation of the structural data is
supported by the electrophysiological studies,
including nerve conduction and electromyo-
graphic experiments in PBGD–/– mice. In par-
ticular, there were no signs of primary demyeli-
nation (temporal dispersion, slowing of nerve
conduction, increase of latencies; Table 2 and
Figure 5). Mild admixed demyelination, indicated by mild
temporal dispersion, occurred only in the most severely
affected PBGD–/– mice with a very low M-response. The
most prominent electromyography (EMG) finding in
PBGD–/– mice was a severe chronic neurogenic pattern
with decreased MUAP recruitment, increased MUAP
amplitudes, and polyphasia. Although we may not have
achieved maximal innervation, we show that normal mice
achieve a dense interference pattern under our experi-
mental conditions, whereas PBGD–/– mice recruit high-
amplitude MUAPs relatively early without achieving a
dense interference pattern. This is due to a loss of motor
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Figure 3
Electron microscopy of pathological alterations of quadriceps nerves in six-month-old PBGD–/– mice. (a) A myelinated axon (A) is surrounded by basal lam-
ina–covered Schwann cell profiles (arrows) reminiscent of bands of Büngner. Arrowheads point to empty basal laminae. (b) Schwann cells devoid of axon
and myelin (arrows) form profiles reminiscent of bands of Büngner. Arrowheads point to Schwann cell basal laminae. (c) This axonal profile (asterisk) con-
taining numerous vesicles (small arrows) is reminiscent of a growth cone usually found in injured nerves. Note the close association with a Schwann cell (large
arrows). Arrowheads point to Schwann cell basal laminae. (d) Two small-caliber axons (asterisks), probably axonal sprouts, are in close association with a
Schwann cell profile (arrows) reminiscent of a band of Büngner. Arrowheads point to Schwann cell basal laminae. Scale bars: 0.5 m m
Table 2
Nerve conduction and electromyography
Nerve conduction of sciatic nerve
Control (+/+) PBGD–/–
(n = 18) (n = 23)
Proximal stimulation
Latency (ms) 1.5 – 0.2 1.6 – 0.3
Amplitude (mV) 14 – 4 10 – 5A
F-latency (ms) 4.4 – 0.6 4.7 – 1.1
Distal stimulation
Latency (ms) 0.9 – 0.2 1.0 – 0.3
Amplitude (mV) 17 – 5 12 – 5A
F-latency (ms) 4.8 – 0.6 4.9 – 1.6
Motor nerve conduction 41 – 12 41 – 9
Velocity (ms)
Mixed-afferent nerve conduction velocity (ms) 56 – 17 51 – 12
The data are expressed as mean – SD. ADifference of means between control and PBGD–/– mice;
P < 0.05, double-sided U test.
Electromyography
Muscle Control (+/+) PBGD–/–
(n = 4) (n = 5)
Gluteus maximus 425 m VB (100–3,000; n = 50) 960 m V (200–6,000; n = 93)
Quadriceps 400 m VB (180–1,400; n = 53) 970 m V (190–3,000; n = 38)
Gastrocnemius 390 m VB (120–840; n = 41) 1,600 m V (500–3,390; n = 15)
The data are given as medians (range, number of motor units analyzed). BThe differences of the
medians between the control and PBGD–/– mice were significantly different in all three muscles;
P < 0.05, double-sided U test.
units and corresponds to the lower compound muscle
action potential (CMAP) amplitudes in the sciatic nerve
conduction studies.
The results of these nerve conduction studies in
PBGD–/– mice are consistent with electrophysiological
findings in patients with porphyric neuropathy who suf-
fer from an axonal neuropathy that predominantly affects
motor fibers with little electrophysiological evidence of
demyelination (6, 20–22). EMG findings in human por-
phyric neuropathy usually reveal decreased recruitment of
MUAPs shortly after onset of weakness, with pathological
spontaneous activity first appearing in proximal muscles
and later spreading to distal muscles (20, 21).
The behavioral, structural, and electrophysiological
data in PBGD–/– mice provide convincing evidence that
porphyric neuropathy is primarily an axonal motor neu-
ropathy and that the additional changes described most
likely are the result of repeated events leading to degen-
eration and regeneration.
A number of hypotheses have been proposed to explain
the pathogenesis of porphyric neuropathy, but none has
been directly tested. Increased ALA synthase activity, accu-
mulation of ALA, and heme deficiency in the liver are bio-
chemical features common to all acute porphyrias. Expla-
nations that link these biochemical changes to neuronal
dysfunction implicate ALA as a neurotoxin and/or propose
decreased functions of specific hemeproteins. The almost
invariable association of clinical symptoms with high lev-
els of ALA in serum and urine and the demonstration of in
vitro effects of ALA in neurophysiological test systems,
albeit usually observed at concentrations unlikely to occur
in acute porphyria, led to the prevailing consideration of
ALA as a neurotoxin. However, the results reported here
reveal that highly increased ALA levels are not a prerequi-
site for peripheral neuropathy, as mice developed progres-
sive neuropathology without high levels of ALA. Rather,
the data suggest that heme deficiency in the liver or nerv-
ous system could lead to decreased levels of key hemepro-
teins such as mitochondrial cytochromes, tryptophan
dioxygenase, nitric oxide synthase, or soluble guanylate
cyclase in various tissues, resulting in indirect or direct
effects in motor neurons.
Preliminary investigations of a number of hemepro-
teins support this possibility. Thus, mitochondria iso-
lated from liver of PBGD–/– mice displayed decreased
oxygen consumption presumably due to decreased func-
tion of hemeproteins of the respiratory chain, and tryp-
tophan levels were elevated in the brain of PBGD–/– mice,
although only after phenobarbital treatment (Lindberg,
R.L.P., et al., unpublished observations), similar to stud-
ies reported by Litman and Correia (23) in a model of
chemically induced porphyria in rats. On the other hand,
extensive studies in our laboratory of heme-dependent
dimerization, enzymatic activity, and induction of neu-
ronal nitric oxide synthase did not reveal differences
between PBGD–/– mice and controls (Lindberg, R.L.P.,
and Meyer, U.A., unpublished observations). Thus, the
role of heme deficiency and its differential effects on var-
ious hemeproteins in the generation of porphyric neu-
ropathy require further study.
Many patients carrying the specific enzyme defects of
acute porphyrias have no clinical symptoms. Clinical
manifestations reflecting neuropathy frequently are pre-
cipitated by drugs, hormones, and fasting. These factors
are known to induce or increase the inducibility of
hepatic ALA synthase (1, 2, 6). After an acute attack,
most symptoms are reversible.
However, in the animal model of acute porphyria
described here, the neuropathy developed progressively
with age and in the absence of high levels of ALA. In
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Figure 4
Electron microscopy of pathological features indicative of axon degener-
ation of quadriceps and saphenous nerves in six-month-old PBGD–/– mice.
(a and b) The axon of this fiber is characterized by a complete disorgani-
zation of its cytoskeletal elements and by electron-dense material apposed
to the axolemma (arrows in a). The high-power electron micrograph (b)
reveals an interrupted axon membrane (arrowheads). The periaxonal com-
partment is poorly defined. (c and d) These fibers are characterized by
axonal loss and a contortion of the remaining myelin profiles, a feature
reminiscent of Wallerian degeneration. Note denervated Schwann cell
reminiscent of a band of Büngner at the upper-right corner in c (arrow).
Asterisk in c is on an endoneurial fibroblast. (e) In the quadriceps nerve,
the Schwann cells form abnormal processes protruding into the endoneur-
ial space (arrows). (f) The myelinated and nonmyelinated fibers of the
saphenous nerve are not distinguishable from fibers of wild-type mice.
Note the individual ensheathment of each axon by a process of the non-
myelinated Schwann cell (small arrows). Scale bars: 0.5 m m
PBGD–/– mice, therefore, axonal neuropathy most likely
develops as a consequence of subacute or chronic heme
deficiency. Mild chronic peripheral neuropathy was also
documented by Mustajoki and Seppäläinen (24) in
patients with latent porphyria, even in patients who
never had acute symptoms, by decreased conduction
velocity of slow motor fibers.
The animal model of acute porphyria described here
thus shows similarities and differences to the human dis-
ease. For instance, although phenobarbital resulted in a
massive induction of hepatic ALA synthase and conse-
quent accumulation of plasma ALA to levels observed in
patients during acute attacks (Table 3), mice did not man-
ifest acute and reversible symptoms such as paralysis or
seizures, and the motor disturbance was not visibly aggra-
vated by the drug treatment. Moreover, there were no
obvious signs of autonomic neuropathy such as tachycar-
dia or a change in eating behavior in PBGD–/– mice, except
for a slight but significant increase in blood pressure
(Lindberg, R.L.P., unpublished observations).
The reasons for these discrepancies are unclear at this
time. We consider it unlikely that the differences in phe-
notype are due to the lower activity of PBGD in mice
( ~ 30% of normal activity) compared with the 50%
decrease in AIP patients. The Vmax of PBGD in humans is
normally about twice as high as the Vmax (uninduced) of
ALA synthase (25), making it the second rate-limiting
step. In C57BL/6 mice, however, we found the PBGD
activity to be four to five times higher than that of ALA
synthase. In our model, therefore, the enzyme deficien-
cy was adjusted to the species difference between mouse
and human liver to produce the same drug-induced bio-
chemical changes in ALA synthase induction and ALA
accumulation. Since acute porphyria shows extremely
variable penetrance and expressivity, PBGD–/– C57BL/6
mice may reflect only one of the possible phenotypes of
the human disease.
In conclusion, we show that mice deficient in PBGD
develop motor dysfunction and peripheral neuropatho-
logical features closely resembling those of patients with
inherited acute porphyrias. The axonal neuropathy
occurs in the absence of high levels of ALA. These data
suggest that heme deficiency and consequent dysfunc-
tion of hemeproteins can cause porphyric neuropathy.
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Figure 5
Neurophysiological abnormalities in PBGD–/– mice. (a) CMAP record-
ings from the foot muscles after proximal stimulation of the sciatic
nerve. Note the different amplitude scales. PBGD–/– mouse and con-
trol were 16 months old. A decrease of the M-response amplitude and
temporal dispersion can be seen in the PBGD–/– mouse. The arrow
denotes the onset of the M-response, and F represents F-wave.
Redrawn from original recordings. (b) Polyphasic MUAP recorded in
the greater gluteal muscle of a PBGD–/– mouse. (c) Representative elec-
tromyography recordings from a PBGD–/– mouse (upper traces) and a
control mouse (lower traces) during maximal withdrawal. Note the
dense interference pattern in the control mouse, which was not
achieved by the PBGD–/– mouse, and the higher MUAP amplitudes in
the PBGD–/– mouse.
Table 3
ALA concentrations in PBGD–/– and control mice, and in patients with acute intermittent porphyria
Genotype Plasma Urine Striatum Peripheral tissueA
(m M) ( m mol/ m mol creatinine) (nM) ( m M)
No treatment PBGD–/– 0.27 – 0.15 (n = 35)B 0.034 – 0.015 (n = 42)B ND NA
No treatment Control (+/+) 0.12 – 0.07 (n = 23) 0.019 – 0.003 (n = 36) ND 0.03 – 0.02
(n = 4)
Phenobarbital PBGD–/– 14.01 – 8.90 (n = 33)B 1.159 – 0.741 (n = 17)B 56.01 – 39.86 (n = 7) 1.92 (n = 2)
Phenobarbital Control (+/+) 0.28 – 0.10 (n = 32) 0.019 – 0.013 (n = 30) 2.36 – 0.89 (n = 6) 0.05 (n = 1)
Plasma Urine CSF 
(m M) (m mol/ m mol creatinine) ( m M)
AIP patients, 
symptomatic 1.8–13 (refs. 11, 26; range, n = 34) 0.005–0.164 (ref. 27) 0.027–2.1 (refs. 7, 11, 28, 29; range, n = 4)
Normal 0.1 ± 0.04 (n = 89) <0.004 (ref. 27)
Data are given as mean ± SD, except where indicated. PBGD–/– mice are compared with age-matched control mice. Mice were treated with phenobarbital intraperitoneally
daily on four consecutive days with increasing doses (100, 110, 120, and 125 mg/kg); data represent combined values at 36 and 60 h after phenobarbital treatment. AThe
microdialysis probe was placed near the tibial nerve of the hindleg. BP < 0.001. CSF, cerebrospinal fluid; NA, not analyzed; ND, not detectable.
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